WO2005105066A3 - Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases - Google Patents

Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases Download PDF

Info

Publication number
WO2005105066A3
WO2005105066A3 PCT/IT2005/000248 IT2005000248W WO2005105066A3 WO 2005105066 A3 WO2005105066 A3 WO 2005105066A3 IT 2005000248 W IT2005000248 W IT 2005000248W WO 2005105066 A3 WO2005105066 A3 WO 2005105066A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
histone deacetylases
hyperlipidaemias
cardiovascular diseases
inhibitors against
Prior art date
Application number
PCT/IT2005/000248
Other languages
French (fr)
Other versions
WO2005105066A2 (en
WO2005105066A8 (en
Inventor
Maurizio Crestani
Cristina Godio
Nico Mitro
Original Assignee
Univ Degli Studi Milano
Maurizio Crestani
Cristina Godio
Nico Mitro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Milano, Maurizio Crestani, Cristina Godio, Nico Mitro filed Critical Univ Degli Studi Milano
Priority to EP05742909A priority Critical patent/EP1746982A2/en
Publication of WO2005105066A2 publication Critical patent/WO2005105066A2/en
Publication of WO2005105066A8 publication Critical patent/WO2005105066A8/en
Publication of WO2005105066A3 publication Critical patent/WO2005105066A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to the use of inhibitors of the histone deacetylases for the preparation of a medicament for the treatment of pathologies caused by increased levels of plasma cholesterol and plasma and hepatic triglycerides. Particularly, the invention relates to the use of said inhibitors for the preparation of a medicament for the treatment of diseases such as hyperlipidaemia, particularly, hypercholesterolaemia, hypertriglyceridaemia, atherosclerosis, cardiovascular and cerebrovascular pathologies, obesity, diabetes metabolic syndromes.
PCT/IT2005/000248 2004-04-30 2005-04-29 Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases WO2005105066A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05742909A EP1746982A2 (en) 2004-04-30 2005-04-29 Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis and cardiovascular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000876A ITMI20040876A1 (en) 2004-04-30 2004-04-30 DEHACETYLASE-HDAC HISTONE INHIBITORS-WHICH HYPOLIPIDEMIZED AGENTS FOR THE THERAPY AND PREVENTION OF ARTERIOSCLEROSIS AND CARDIOVASCULAR DISEASES
ITMI2004A000876 2004-04-30

Publications (3)

Publication Number Publication Date
WO2005105066A2 WO2005105066A2 (en) 2005-11-10
WO2005105066A8 WO2005105066A8 (en) 2006-04-13
WO2005105066A3 true WO2005105066A3 (en) 2006-05-18

Family

ID=34979580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2005/000248 WO2005105066A2 (en) 2004-04-30 2005-04-29 Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases

Country Status (3)

Country Link
EP (1) EP1746982A2 (en)
IT (1) ITMI20040876A1 (en)
WO (1) WO2005105066A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2650520A1 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
MX2009006969A (en) 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Preparation of romidepsin.
WO2008090534A1 (en) * 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
KR100909867B1 (en) * 2007-04-16 2009-07-29 주식회사바이오러넥스 Compositions for the Prevention and Treatment of Osteo Metabolic Diseases
US20140314788A1 (en) * 2010-04-09 2014-10-23 Salk Institute For Biological Studies Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
AU2011279303B2 (en) 2010-07-12 2015-07-16 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
EP2683371B1 (en) * 2011-03-09 2020-10-21 Cereno Scientific AB Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
EP2599481A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment or prevention of various diseases
CN104136410A (en) * 2011-12-29 2014-11-05 药品循环公司 Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
KR102438395B1 (en) 2016-04-08 2022-08-30 세레노 사이언티픽 에이비 Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
BR112022005595A2 (en) 2019-09-27 2022-07-19 Takeda Pharmaceuticals Co COMPOUND, DRUG, METHODS FOR INHIBITING HISTONE DEACETYLASE 6 AND FOR PROPHYLAXIS OR TREATMENT OF ALZHEIMER'S DISEASE OR PROGRESSIVE SUPRANUCLEAR PALSY IN A MAMMAL, AND, COMPOUND USE

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049970A1 (en) * 1997-05-02 1998-11-12 Board Of Regents Of The University Of Nebraska N-methyl-d-aspartate (nmda) receptor blockers for the prevention of atherosclerosis
WO2000066110A1 (en) * 1999-04-29 2000-11-09 Merck Patent Gmbh Glycine cleavage system inhibitors as potential antipsychotics
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP1206936A2 (en) * 2000-06-26 2002-05-22 BURZYNSKI, Stanislaw R. Phenylacetic acid compositions for treating or preventing hypercholesterolemia
US20030185917A1 (en) * 2002-03-27 2003-10-02 Salimath Paramahans Veerayya Synergistic pharmaceutical composition for diabetic nephropathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049970A1 (en) * 1997-05-02 1998-11-12 Board Of Regents Of The University Of Nebraska N-methyl-d-aspartate (nmda) receptor blockers for the prevention of atherosclerosis
WO2000066110A1 (en) * 1999-04-29 2000-11-09 Merck Patent Gmbh Glycine cleavage system inhibitors as potential antipsychotics
EP1206936A2 (en) * 2000-06-26 2002-05-22 BURZYNSKI, Stanislaw R. Phenylacetic acid compositions for treating or preventing hypercholesterolemia
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US20030185917A1 (en) * 2002-03-27 2003-10-02 Salimath Paramahans Veerayya Synergistic pharmaceutical composition for diabetic nephropathy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHUANG D-M: "Lithium protection from glutamate excitotoxicity: therapeutic implications", CLINICAL NEUROSCIENCE RESEARCH, ELSEVIER, LONDON, GB, vol. 4, no. 3-4, December 2004 (2004-12-01), pages 243 - 252, XP004732774, ISSN: 1566-2772 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BELKINA, L. M. ET AL: "The cardioprotective effect of the antiepileptic valproate in cardiac contractile disorders induced by acute myocardial infarction in rats", XP002355811, retrieved from STN Database accession no. 127:257337 *
LOY, REBEKAH ET AL: "Neuroprotective properties of valproate: Potential benefit for AD and tauopathies", JOURNAL OF MOLECULAR NEUROSCIENCE , 19(3), 303-307 CODEN: JMNEES; ISSN: 0895-8696, 2002, XP008056182 *
PATOLOGICHESKAYA FIZIOLOGIYA I EKSPERIMENTAL'NAYA TERAPIYA , (2), 18-21 CODEN: PAFEAY; ISSN: 0031-2991, 1997 *
WOLDEN-HANSON, TAMI ET AL: "Evaluation of a rat model of valproate-induced obesity", PHARMACOTHERAPY , 18(5), 1075-1081 CODEN: PHPYDQ; ISSN: 0277-0008, 1998, XP008056184 *

Also Published As

Publication number Publication date
ITMI20040876A1 (en) 2004-07-30
WO2005105066A2 (en) 2005-11-10
EP1746982A2 (en) 2007-01-31
WO2005105066A8 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2005105066A3 (en) Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases
WO2007084319A3 (en) Diaryl piperidines as cb1 modulators
WO2007118185A3 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074244A3 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2007109354A3 (en) Peptide-peptidase inhibitor conjugates and methods of using same
WO2007056771A3 (en) Compounds for the treatment of metabolic disorders
WO2006074330A3 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2007100535A3 (en) Oxyntomodulin derivatives
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
WO2009042922A3 (en) Peptide-peptidase inhibitor conjugates and methods of making and using same
EP2206180A4 (en) Preparation process for preventing deformation of jelly-roll type electrode assembly
WO2016105118A3 (en) Biaryl derivative as gpr120 agonist
WO2007095601A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
WO2010081079A3 (en) Composition and method for treatment of diabetes
WO2012006298A3 (en) Formulation for co-therapy treatment of diabetes
EP2579876A4 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
HK1125831A1 (en) Fat accumulation inhibitor for the treatment of metabolic syndrome
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
EP2011492A4 (en) Gip secretion inhibitor
WO2011038014A3 (en) Composition and method for treatment of diabetes
WO2010045306A3 (en) Azine derivatives and methods of use thereof
EP2010164A4 (en) S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
EP2114374A4 (en) Pharmaceutical compositions of entacapone
WO2007021735A3 (en) Use of phospholipid arachidonic acids for increasing muscle mass in humans

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 45/2005 UNDER (72, 75) THE ADDRESS OF "MITRO, NICO" SHOULD READ "VIA SAN ROCCO, 12, I-20135 MILANO (IT)."

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005742909

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005742909

Country of ref document: EP